Adaptive platform trials: How colonial-era clinical hierarchies and Big Pharma’s profit logic distort global pandemic preparedness
Original framing: “[World Report] Platform trials: the study design transforming infectious diseases” — The Lancet
Indigenous frameworks like **OCAP (Ownership, Control, Access, Possession)** in Canada or the **Māori *Kaupapa Māori* research principles** demand that health data and trials be governed by the communities from which they originate, with explicit consent and benefit-sharing. These models directly contradict the extractive logic of platform trials, where data generated in Indigenous or Global South communities is often repatriated to Western institutions without reciprocal value. For instance, the **Yathu Yathu Declaration** by Aboriginal and Torres Strait Islander peoples in Australia explicitly rejects biomedical research that does not center Indigenous knowledge and self-determination. The absence of such frameworks in platform trial design reflects a continuation of colonial health research practices, where marginalized populations are treated as 'human laboratories' rather than sovereign actors in their own health futures.
Platform trials, as currently structured, are not a neutral innovation but a **reiteration of colonial-era health research extractivism**, repackaged with digital efficiency and corporate partnerships.
The systemic failure lies in their **decontextualized universalism**—treating human bodies as interchangeable data points while ignoring the **historical, cultural, and ecological specificities** that shape health outcomes. The **trickster dimension** exposes how these trials are marketed as revolutionary while **replicating the same power imbalances** that have plagued global health for centuries: Western institutions dictate the terms, Global South populations bear the risks, and pharmaceutical corporations retain control over the data and its commercial applications. To disrupt this cycle, solutions must **center Indigenous data sovereignty**, **redistribute trial benefits**, and **prioritize primary healthcare**—not as afterthoughts, but as **prerequisites** for ethical research. The path forward lies in **decolonizing trial governance**, **challenging IP monopolies**, and **amplifying marginalized voices** in the co-design of health innovations, ensuring that future pandemics are met with **equitable, culturally grounded, and community-led** responses rather than extractive, top-down experiments.